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ORIGINAL ARTICLE
Introduction: Commonly reported complications after concurrent 
chemoradiotherapy (CCRT) in patients with stage III non–small-cell 
lung cancer (NSCLC) include febrile neutropenia, radiation esopha-
gitis, and pneumonitis. We studied the incidence of tumor cavitation 
and/or “tumor abscess” after CCRT in a single-institutional cohort.
Methods: Between 2003 and 2010, 87 patients with stage III 
NSCLC underwent cisplatin-based CCRT and all subsequent follow-
up at the VU University Medical Center. Diagnostic and radiother-
apy planning computed tomography scans were reviewed for tumor 
cavitation, which was defined as a nonbronchial air-containing cav-
ity located within the primary tumor. Pulmonary toxicities scored 
as Common Toxicity Criteria v3.0 of grade  III or more, occurring 
within 90 days after end of radiotherapy, were analyzed.
Results: In the entire cohort, tumor cavitation was observed on 
computed tomography scans of 16 patients (18%). The histology in 
cavitated tumors was squamous cell (n = 14), large cell (n = 1), or 
adenocarcinoma (n = 1). Twenty patients (23%) experienced pulmo-
nary toxicity of grade III or more, other than radiation pneumonitis. 
Eight patients with a tumor cavitation (seven squamous cell carci-
noma) developed severe pulmonary complications; tumor abscess 
(n = 5), fatal hemorrhage (n = 2), and fatal embolism (n = 1). Two 
patients with a tumor abscess required open-window thoracostomy 
post-CCRT. The median overall survival for patients with or without 
tumor cavitation were 9.9 and 16.3 months, respectively (p = 0.09).
Conclusions: With CCRT, acute pulmonary toxicity of grade III or more 
developed in 50% of patients with stage III NSCLC, who also had radio-
logical features of tumor cavitation. The optimal treatment of patients 
with this presentation is unclear given the high risk of a tumor abscess.
Key Words: NSCLC, Stage III, Concurrent chemoradiotherapy, 
Tumor cavitation, Toxicity.
(J Thorac Oncol. 2012;7: 1271–1275)
Concurrent chemoradiotherapy (CCRT) is considered to be the standard of care for fit patients who present 
with a stage III non–small-cell lung cancer (NSCLC).1 The 
survival gains observed with CCRT relative to the sequen-
tial administration of both modalities have been attributed 
to improved loco-regional tumor control.2 Increased toxicity 
observed with CCRT includes acute esophagitis and neutro-
penia, with grade III/IV neutropenia reported in  range of 
32% to 43% of patients treated using cisplatin-etoposide and 
concurrent radiotherapy.3–5 A retrospective analysis of late 
complications after CCRT to 66 Gy or higher, reported pul-
monary complications including bronchial stenosis and fatal 
hemoptysis but neither tumor cavitation nor fatal infections 
were mentioned.6
About 10% to 20% of all lung carcinomas present 
with radiological cavitation, which is believed to be due to 
tumor necrosis as a consequence of ischaemia and/or bron-
chial obstruction.7 Earlier reports had observed that cavi-
tated tumors undergoing treatment with chemotherapy and/or 
radiotherapy could result in potentially “serious, difficult-to-
treat infectious complications.”8,9 Awareness of tumor cavita-
tion has increased since this finding was linked to the toxicity 
and efficacy of antiangiogenic agents in NSCLC.10,11
CCRT has been our routine treatment strategy for stage 
III NSCLC since 2003.12 After encountering isolated cases 
of cavitation developing in such, we evaluated the incidence, 
treatment, and outcome of tumor cavitation in consecutive 
patients with stage III NSCLC who underwent CCRT with 
cisplatin-based chemotherapy and concurrent thoracic radio-
therapy, between 2003 and 2010.
PATIENTS AND METHODS
Patients treated at our institution were eligible for the 
present retrospective analysis if all baseline and follow-up 
imaging, and the complete details on pulmonary toxicity and 
follow-up imaging were available. Between 2003 and 2010, a 
total of 243 patients with stage III NSCLC underwent treatment 
with cisplatin-based CCRT, including 22 patients who were 
treated in a phase II trial conducted between 2005 and 2006.13 
Of these 243 patients, we excluded 71 who underwent surgery 
after induction CCRT. Also excluded were 85 patients who 
underwent radiotherapy at our center, but whose systemic 
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chemotherapy and radiological follow-up was performed at 
other referral hospitals. The remaining 87 patients with a stage 
III NSCLC are the subject of this report because all imaging, 
chemotherapy, and follow-up were conducted at our center 
after definitive CCRT.
Details of the treatment scheme for patients treated out-
side trials have been described previously, and eligibility was 
mainly based on fitness to receive full-dose cisplatin-based 
chemotherapy, as well as the percentage volume of lung tissue 
receiving a dose of 20 Gy or more (V
20
).12 The chemotherapy 
schedule consisted of a cycle of induction cisplatin 80 mg/m2 on 
day 1, and gemcitabine 1250 mg/m2 on days 1 and 8, followed by 
cisplatin 80 mg/m2 (days 21 and 42) and etoposide 100 mg/m2 
(days 21–23 and 42–44)  during concurrent thoracic radio-
therapy. Involved-field radiotherapy commenced on day 22, 
with a minimum dose of 46 Gy upto 66 Gy in 2 Gy-fractions 
(5 days/week). The remaining 22 patients with stage III 
NSCLC were treated with CCRT in a phase II trial,13 receiving 
weekly cisplatin and docetaxel on days 1, 8, 15, 22, 29, and 36 
at a dose of 20 mg/m2. Radiotherapy commenced on day 1 in 
once-daily fractions of 1.8 Gy to a maximum dose of 59.4 Gy.
All diagnostic and radiotherapy planning computed 
tomography (CT) scans before the start of CCRT were 
reviewed by two authors (EP and SS) for tumor cavitation, 
which was defined as an air-containing cavity within the pri-
mary tumor and which was not identifiable as an airway. At 
the time these patients were treated, the institutional policy 
was not influenced by the presence of cavities in the tumor.
Subsequently, patient/treatment characteristics,  details 
of pulmonary toxicity of grade III or more (Common Toxicity 
Criteria v3.0) within 90 days after the end of radiotherapy, and 
follow-up data were derived from an institutional database. 
Progression-free and overall survival was calculated using the 
Kaplan-Meier method and calculated from start of chemother-
apy to September 2, 2011. Results are presented as median 
and range or number and percentage. A p value less than 0.05 
was considered statistically significant.
RESULTS
Incidence of Tumor Cavitation and Survival
Characteristics of the 87 eligible patients are summa- 
rized in Table 1. Sixteen patients (18%) had a cavity in the 
primary tumor before the start of CCRT, with maximal cav-
ity diameters ranging between 0.5 and 4.5 cm. In this patient 
group, the histology was squamous cell carcinoma (SCC) 
(n = 14), adenocarcinoma (n = 1), or large-cell undifferenti-
ated carcinoma (n = 1). The CT images showing individual 
tumor cavitations from six patients are presented in Appendix 
1. All but three patients with tumor cavitation, completed their 
planned chemotherapy, and received a minimal radiotherapy 
dose of 46 Gy. Median overall survival for all 87 patients was 
15.2 months, and for patients with or without tumor cavita-
tion, the corresponding values were 9.9 and 16.3 months, 
respectively (log-rank p = 0.09) (Fig. 1). Survival for patients 
with SCC and other histologies did not differ significantly 
(log-rank p = 0.273).
Among patients who did not have pretreatment tumor 
cavitation, two subsequently developed a cavitation in the 
tumor within 3 months of completing CCRT. In addition, three 
more patients developed pulmonary cavitations in the setting 
of a postobstructive pneumonia.
Pulmonary Toxicity of Grade III or More, and 
Follow-Up of Patients
Eight of 16 patients (50%) with pretreatment tumor 
cavitation developed acute pulmonary toxicity of grade  III or 
more,  other than radiation pneumonitis, as opposed to only 
12 of 71 (17%) in those without tumor cavitation. Table 2 sum-
marizes details of all 20 patients developing acute pulmonary 
toxicity of grade III or more. Two patients with large cavi-
tated tumors died of massive pulmonary hemorrhage 1 month 
after start of the treatment. Another patient died 2 weeks after 
the end of radiotherapy (46 Gy) from pulmonary embolism. 
Infection, presenting as an air-fluid level in the tumor cavita-
tion (tumor abscess) on radiological imaging, was observed in 
the five remaining patients. Of these, one patient was hospital-
ized and treated with intravenous (IV) administration of antibi-
otics during CCRT, but died shortly after treatment. The other 
four were hospitalized 10, 13, 21, and 87 days, respectively, 
after the end of radiation treatment. Of the latter, two patients 
recovered after IV administration of antibiotics, and subse-
quently developed intrathoracic disease progression after 18.5 
and 27 months. Two remaining patients underwent (multiple) 
surgical intervention(s), which consisted of open-window tho-
racostomy and muscle transposition into the thoracic cavity. 
Aspergillus fuminatus was reported in pathological specimens 
derived from cavities of both patients. Despite surgical inter-
vention, one patient died of postoperative complications and 
the other died of massive bleeding from the ipsilateral pulmo-
nary artery 8.9 months after surgery.
The eight patients with baseline tumor cavitation, who 
did not develop any acute pulmonary toxicity of grade III or 
more, had intrathoracic disease progression within 7.3 months 
(n = 3), brain metastasis manifesting between 4.6 and 15.5 
months (n = 3), or bone metastasis after 3.4 months (n = 1) as 
first site of recurrence. Only one patient was alive after 48.8 
months without progression of disease.
DISCUSSION
The use of bi- and trimodality treatment strategies in 
patients with stage III NSCLC has increased awareness of the 
potential for severe treatment-related toxicity. We observed 
an 18% incidence of pretreatment tumor cavitation in 87 
consecutive patients with stage III NSCLC at our center, with 
half developing acute pulmonary toxicity of grade III or more, 
including five patients with grade V complications. Despite 
a lack of consistent published data on the prognostic role of 
pretreatment tumor cavitation,7–9 patients in our study cohort 
with cavitated tumor developed serious complications during 
or after CCRT.
The etiology of the observed toxicity is unclear. CCRT 
increases the likelihood of high-grade neutropenia; in our 
cohort, six of 10 patients who developed pneumonia of grade 
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III or more and/or abscess, had experienced leucocytopenia of 
grade III or more. Both the tumor cavitation (in SCC) and leu-
cocytopenia may have increased the risk of developing infec-
tious complications. However, 48 other patients with grade 
III/IV leucocytopenia did not experience these problems, a 
group that included 20 with SCC. Of the total cohort, five 
patients developed an infection and/or abscess in the tumor 
cavity, representing 6% of all patients.
To the best of our knowledge, no previous reports have 
highlighted such a high incidence of complications related to 
tumor cavitation during or after CCRT in phase III trials or 
recent meta-analyses.2–5,14 Publications of randomized clini-
cal trials may have failed to identify some clinical toxicities, 
as a result of patient selection and insufficient follow-up15. In 
addition, regional differences in the incidence of squamous-
cell tumors may also have contributed to under-reporting. For 
example, only 33% of patients in a large phase III CCRT trial 
from the United States had SCC,4 whereas 43% of patients in 
the present study had  SCC. In the Netherlands, the proportion 
of non-SCCs increased between the periods 1989 to 1993 and 
2004 to 2009, from 42% to 67% for male patients and from 
67% to 81% for female patients.16
Yet another explanation for the observed tumor 
cavitations and complications could be the relatively large 
primary tumor size in our patients, as 30% had a tumor 
measuring 8 cm or larger. A recent report suggests that many 
European centers consider tumors measuring more than 
8 to 10 cm to be suitable for only palliative treatment.17 
Similarly, a recent European Organisation for Research and 
Treatment of Cancer (EORTC)  study excluded patients if the 
tumor volume required a radiation field encompassing 12 cm 
or more of the esophagus in the high-dose region.18
High-dose radiotherapy may contribute to tumor cavita-
tion because of radiation-induced decreases in regional lung 
perfusion,19 and central tumor necrosis has also been observed 
after two fractions of 18 Gy in patients undergoing stereotactic 
radiotherapy.20 Although fluoro-2-deoxy-D-glucose positron 
emission tomography may also identify central tumor necrosis, 
baseline tumor cavitation identified on fluoro-2-deoxy-D-glu-
cose positron emission tomography has not been shown to be 
a poor prognostic feature.21 However, it should be pointed out 
that patients in the last mentioned report did not undergo CCRT.
A study of transthoracic aspirates from cavitating tumors 
showed that six of seven febrile patients had positive aspiration 
cultures at diagnosis.22 Since 2009, cone-beam CT scans are rou-
tinely performed during the course of radiotherapy at our center, 
and this can potentially facilitate the earlier detection of tumor 
cavitation and/or abscess during CCRT. Early identification of 
tumor cavitation may indicate a need for treatment using appro-
priate antibiotics. Surgical management of lung abscess has been 
previously described in 247 patients, excluding abscesses sec-
ondary to carcinoma.23 Despite conservative treatment in all, 119 
and 58 patients underwent subsequent surgical drainage or pul-
monary resection, respectively. Surgical drainage cured 67.2% 
of patients, 11.8% improved but needed additional interven-
tions, and 21% died. Two of the patients in our report underwent 
open-window thoracostomy for acute complications of a tumor 
abscess within 5 months post-CCRT, after failure to respond to 
the IV administration of antibiotics. Nevertheless, one died of 
postoperative complications. Currently, we consider early surgi-
cal drainage when conservative treatment strategies fail.
Some limitations of the present study must be recog-
nized, one of which is the fact that it is restricted to patients in 
whom all follow-up was performed within the VU University 
Medical Center. Although overall survival between patients 
with or without tumor cavitation was not significantly differ-
ent in this relatively small study, our findings suggest caution 
when using CCRT in this setting.
We postulate that primary surgical resection with post-
adjuvant chemoradiotherapy in patients who are potentially 
TABLE 1.  Patient and Treatment Characteristics (n = 87)
Characteristic Patients
Sex
 Male 61 (70%)
 Female 26 (30%)
Age (yrs)
 Median (range) 60 (42–80)
Clinical staging
 Stage IIIA 36 (41%)
 Stage IIIB 51 (59%)
Histology
 Squamous-cell carcinoma 37 (43%)
 Adenocarcinoma 28 (32%)
 Large-cell carcinoma 22 (25%)
Maximum size of primary tumor (n=83)
 All tumors (median) 6 cm
 Squamous-cell carcinoma (median) 7 cm
 Percentage of tumors ≥8 cm 26 (30%)
Concurrent chemotherapy
 Cisplatin-etoposide (3-weekly) 75 (86%)
 Cisplatin-docetaxel (weekly) 12 (14%)
Total radiation dose (Gy)
 <60 38 (44%)
 60 21 (24%)
 >60 28 (32%)
Leucocytopenia grade ≥III (n)
 Squamous-cell carcinoma 25
 Nonsquamous-cell carcinoma 29
Radiation pneumonitisa
 Grade II 13
 Grade III 4
aScored according to Common Toxicity Criteria v3.0.
FIGURE 1. Overall survival for patients with or without 
tumor cavitation. ©+, patients with cavitated tumors; ©−, 
patients with noncavitated tumors.
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resectable could be a strategy to prevent complications of tumor 
cavitation. In addition, administration of weekly low-dose che-
motherapy is potentially a less toxic alternative. Finally, evi-
dence of infection in a developing cavity requires aggressive 
antibiotic treatment and probably early surgical intervention.
APPENDIX 1
Pretreatment tumor cavitation in six study patients.
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